News

First Patient Dosed with TLX250-CDx in Italy for ccRCC

The below product is manufactured at RTM First Patient dosed with TLX250-CDx in Italy for ccRCC Th...

📢 Important update on EU #GMP Annex 1 at #ESRR2024!  The revised EU GMP Annex 1, effecti...

ABX has received marketing authorisation for the radiotracer Radelumin® in Germany! This marks the 8...

The below product is manufactured at RTM First Patient Dosed in Phase II Study of TLX250-CDx in Tri...

Klaudia Cybulska (postdoc radiochemistry) has written an article about Huntington's Disease. Abstra...

It is with great pleasure that we announce our cooperation with Alliance Medical Group (AMG) regardi...

We are happy to announce that RTM has received marketing authorization for 18F-FDG of 17 July 2018....

On May 21st, the first patient dosis of QuiremSpheres was processed at RTM and then shipped to the s...

Employees from RTM and Radboudumc have published a new article: 'Production of novel diagnostic radi...

Radboud Translational Medicine will perform the dispensing of below product. The production and dis...

Fluorodopa (18F) is now available for clinical studies and - with doctor's certificate - for routine...

Today we received our GMP-certificate!The results of the inspection were excellent and no shortcomin...

From October 15 to October 19, Radboud translational medicine will attend the 29th annual congress o...